Psoriasis Research Institute of Guangzhou

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Psoriasis Research Institute of Guangzhou sits in the upper half of US sponsors by registered trial count (#4,885 of 15,742 sponsors by registered trial count).

2 total trials 1 currently recruiting 1 completed upper half by trial count

Psoriasis Research Institute of Guangzhou: 2 sponsored US clinical trials, 1 recruiting.

Psoriasis Research Institute of Guangzhou sponsors 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 1 completed. 1 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Phase III, with 1 trials.

Mid-pack sponsor footprint

Psoriasis Research Institute of Guangzhou is in the upper half of sponsors by trial count (#4,885 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.

What is open in the Psoriasis Research Institute of Guangzhou pipeline

1 recruiting of 2 indexed (50% open); 1 completed (50%).

Phase mix: 1 late (III/IV) vs 1 early (I/II) (balanced across stages).

Top condition: Phase III (1 trial), 2 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Psoriasis Research Institute of Guangzhou: open-pipeline peers nationwide

Peers matched on 2 registered trials and 50% open enrollment, not the therapeutic-area sidebar.

Psoriasis Research Institute of Guangzhou sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 1.522.533.544.5 0%20%40%60% Total trials Recruiting share Psoriasis Research Institute of Guangzhou1200 Pharma1ST Biotherapeutics3 Waves Wellness3EO Health3ive Labs60 Degrees Pharmaceuticals7 Hills PharmaAbcentra
Psoriasis Research Institute of Guangzhou sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Psoriasis Research Institute of Guangzhou sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 2 trials (± recruiting share)

Sponsors near 50% open enrollment (± trial volume)

What to do with this Psoriasis Research Institute of Guangzhou page

2 registered trials is a research-attention snapshot, not an endorsement of Psoriasis Research Institute of Guangzhou or any single study.

  • 1 of Psoriasis Research Institute of Guangzhou's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Phase III is the condition Psoriasis Research Institute of Guangzhou studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Phase III trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Psoriasis Research Institute of Guangzhou pipeline card: 2 registered trials from official public datasets.Report a data error.